<i>In Vitro</i> and <i>In Vivo</i> Interactions between the HDAC6 Inhibitor Ricolinostat (ACY1215) and the Irreversible Proteasome Inhibitor Carfilzomib in Non-Hodgkin Lymphoma Cells
- DOI
- 10.1158/1535-7163.mct-14-0220
- Published
- 2014-12-01
- Container
- Molecular Cancer Therapeutics
- Publisher
- American Association for Cancer Research (AACR)
- Open access
- unknown
Credibility signals
serious concern Score 29/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- serious concernRetraction Watch retraction: 1 retraction notice matched this DOI.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1158/1535-7163.mct-14-0220,
title = {<i>In Vitro</i>
and
<i>In Vivo</i>
Interactions between the HDAC6 Inhibitor Ricolinostat (ACY1215) and the Irreversible Proteasome Inhibitor Carfilzomib in Non-Hodgkin Lymphoma Cells},
author = {Girija Dasmahapatra and Hiral Patel and Johnathan Friedberg and Steven N. Quayle and Simon S. Jones and Steven Grant},
year = {2014},
journal = {Molecular Cancer Therapeutics},
doi = {10.1158/1535-7163.mct-14-0220},
url = {https://doi.org/10.1158/1535-7163.mct-14-0220}
}RIS
TY - JOUR
TI - <i>In Vitro</i>
and
<i>In Vivo</i>
Interactions between the HDAC6 Inhibitor Ricolinostat (ACY1215) and the Irreversible Proteasome Inhibitor Carfilzomib in Non-Hodgkin Lymphoma Cells
AU - Girija Dasmahapatra
AU - Hiral Patel
AU - Johnathan Friedberg
AU - Steven N. Quayle
AU - Simon S. Jones
AU - Steven Grant
PY - 2014
JO - Molecular Cancer Therapeutics
DO - 10.1158/1535-7163.mct-14-0220
UR - https://doi.org/10.1158/1535-7163.mct-14-0220
ER - APA
Dasmahapatra, G., Patel, H., Friedberg, J., Quayle, S. N., Jones, S. S., & Grant, S. (2014). <i>In Vitro</i> and <i>In Vivo</i> Interactions between the HDAC6 Inhibitor Ricolinostat (ACY1215) and the Irreversible Proteasome Inhibitor Carfilzomib in Non-Hodgkin Lymphoma Cells. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-14-0220
Source records
- crossref · retrieved 2026-09-26T10:20:20.070Z